More RET-specific or selective RET inhibitors (SRIs; selpercatinib and pralsetinib) were developed and were subsequently approved and are now established as standard of care treatment across a variety of indications including lung and thyroid cancer. This evidence concerns the gene RET and thyroid cancer.